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Abstract
Background: Despite extensive and persistent activation of microglia in multiple sclerosis (MS), microglia inhibitors
have not yet been identified for treatment of the disorder. We sought to identify medications already in clinical use
that could inhibit the activation of microglia. On the basis of the reported inhibitory effects of dipyridamole on
phosphodiesterase activity that result in the production of various anti-inflammatory outcomes, we selected it for
study. Dipyridamole is used clinically for secondary prevention in stroke. In this study, dipyridamole was examined
using microglia in culture and in the mouse model of MS, experimental autoimmune encephalomyelitis (EAE).
Results: We found that dipyridamole attenuated the elevation of several cytokines and chemokines in human
microglia caused by Toll-like receptor stimulation. Morphological characteristics of activated microglia in culture
were also normalized by dipyridamole. In mice, dipyridamole decreased the clinical severity of EAE and reduced
microglial activity and other histological indices of EAE in the spinal cord.
Conclusions: Dipyridamole is an inhibitor of microglia activation and may have a role in MS and other neurological
conditions to attenuate microglial activity.
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Background
Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system (CNS)
characterized by axonal and neuronal injury and loss. A
predominant group of inflammatory cells in active
plaques are highly activated phagocytic macrophages
and microglia [1-3]. Because activated microglia cannot
be reliably differentiated from blood-derived macro-
phages that have infiltrated the CNS, these cells are
often collectively referred to as macrophages/microglia.
Activated macrophages/microglia persist through sec-
ondary progressive MS [2].
The chronic presence of activated macrophage/micro-
glia in MS is likely undesirable for several reasons. First,
a strong correlation is observed between macrophage/
microglia activity and both acute axonal injury [4,5] and
loss of oligodendrocytes [6]. Second, medium condi-
tioned by microglia kills oligodendrocytes in culture [7];
in MS lesions, microglia in the process of stripping mye-
lin can be found [8]. Third, there is persistent activation
of microglia in relapsing-remitting experimental auto-
immune encephalomyelitis (EAE) even after CD4+ num-
ber wanes [9]. Finally, reducing macrophage/microglia
activity with clodronate liposomes or genetic deletion al-
leviates disease activity in EAE [10,11].
Immunomodulators currently used in MS do not tar-
get microglial activity directly, and therefore the persist-
ent macrophage/microglia activation within the CNS
parenchyma remains a therapeutic gap. The tetracycline
derivative, minocycline, has microglia inactivating prop-
erties in addition to other actions (reviewed in [12,13])
and is currently in a phase III trial in early MS
(ClinicalTrials.gov identifier NCT00666887) following
upon encouraging results in small trials in relapsing-
remitting MS [14,15]. We have sought other approved
medications with microglia-inhibitory activity for their
potential utility in MS.
Dipyridamole has multiple known physiological effects
[16]. It is primarily recognized as a platelet inhibitor and
is used in combination with low-dose aspirin for second-
ary prevention in stroke [17]. Its antiplatelet mechanism
is due in part to inhibition of adenosine uptake into
platelets. The increased extracellular concentration of
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adenosine results in vasodilation. The combination of
platelet inhibition and vasodilation promotes improved
tissue perfusion. Dipyridamole also inhibits adenosine
deaminase, which normally breaks down adenosine into
inosine, further increasing concentrations of extracellu-
lar adenosine. Adenosine also has both neuroprotective
and anti-inflammatory roles [18,19]. Dipyridamole is a
phosphodiesterase inhibitor, which results in various
anti-inflammatory outcomes [20,21]. Indeed, as a result
of the phosphodiesterase-inhibitory activity, dipyrid-
amole reduces the level of tumor necrosis factor α
(TNF-α) produced by activated rodent microglia in cul-
ture [22,23]. TNF-α is an important proinflammatory
factor at sites of injury and therefore is an attractive tar-
get for immunomodulatory therapy [24]. Recently, the
anti-inflammatory roles of dipyridamole were utilized in
a rat model of arthritis, where the results showed that
prophylactic treatment reduced the arthritis-associated
pathology [25].
To the best of our knowledge, there have been no
published reports to date of the effect of dipyridamole in
MS or EAE. Given that current MS therapies do not
target microglial activity to any significant extent and
that dipyridamole is an approved medication, we tested
the utility of dipyridamole as an inhibitor of microglial
responses. We have found that dipyridamole affects vari-
ous aspects of microglial activity in culture and that
dipyridamole-treated mice had reduced clinical and
histological outcomes of EAE corresponding to reduced
macrophage/microglia activity.
Results
Microglia are not killed by dipyridamole
We tested dipyridamole on the viability of microglia and
found that concentrations that can be achieved in
humans after oral consumption (1 to 20 μM) [26] did
not reduce cell viability (Figure 1A). These concen-
Figure 1 Nontoxic concentrations of dipyridamole reduce
TNF-α levels and phagocytic capacity of activated microglia.
(A) An ATP luminescence assay demonstrates that dipyridamole does
not adversely affect viability to at least 20 μM. (B) TNF-α increases due to
the addition of lipopolysaccharide (LPS) to microglia are attenuated by
dipyridamole in a concentration-dependent fashion. **P < 0.01, ***P <
0.001 compared to LPS group. All values are means ± SEM (n = 4 wells
per column) and were reproduced in three separate experiments. (C)
The phagocytic capacity of microglia (Iba-1 label, red) is demonstrated by
their ingestion of microfluorospheres (green) that were added to the
culture medium. Note that this is an example of beads captured in a cell
and that the quantitation in panel (D) depicts the results captured from
all the cells in each well. Original magnification, ×200. (D) The total
increase in bead intensity per cell due to LPS activation is attenuated
by 10 μM dipyridamole (DP). Mean ± SEM of four wells per
column. ***P < 0.001.
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trations of dipyridamole were used for the remainder of
the experiments.
Microglia from adult human brain were incubated
with lipopolysaccharide (LPS) or LPS with dipyridamole,
and the conditioned medium was harvested after 24 h.
LPS increased TNF-α, but this effect was attenuated by
concomitant treatment with dipyridamole (Figure 1B).
Similar results (data not shown) were observed for fetal
human microglia and for monocytes from the peripheral
blood of adult volunteers.
We performed a phagocytosis assay to measure the
function of microglia. Microglia were treated for 48 h
with LPS with or without dipyridamole. Microfluo-
rospheres were then added to the culture. Labeling of
microglia with anti-Iba1 indicated ingestion of the
fluorospheres (Figure 1C). Uptake of the fluorospheres
was quantified by determining the total intensity of the
fluorospheres within the microglia using algorithms
developed in MATLAB (MathWorks, Natick, MA, USA)
(Figure 1D). LPS increased the capacity of microglia to
phagocytose the fluorospheres, but this effect was atten-
uated by the presence of dipyridamole (Figure 1D).
Next, conditioned medium from microglia cultures was
subjected to a 25-cytokine multiplex assay to determine
the spectrum of molecules affected by dipyridamole.
Selected molecules are displayed in Figure 2, but all results
demonstrated a similar trend. Treatment with LPS or a
Toll-like receptor 2 agonist, Pam, increased the secretion
of proinflammatory molecules, but in all cases this effect
was suppressed by dipyridamole (Figure 2).
Figure 2 The increase of multiple cytokines and chemokines following LPS or PAM activation of microglia is attenuated by
dipyridamole. 25-cytokine multiplex ELISA permitted measurement of granulocyte-macrophage colony-stimulating factor, interferon α
(IFN-α), IFN-γ, interleukin 1ra (IL-1ra), IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-γ-inducible protein 10 (IP-10),
monocyte chemoattractant protein 1 (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein 1α (MIP-1α), MIP-1β, RANTES
(regulated on activation, normal T cell expressed and secreted), eotaxin and TNF-α in the cell culture supernatant. LPS and Pam increased the
levels of all inflammatory molecules, and all were attenuated by dipyridamole (20 μM). These data were reproduced in a second microglia culture.
Only eight of the molecules are displayed.
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Dipyridamole normalizes cell morphology
We next compared the morphological characteristics of
control (untreated) microglia with those exposed to LPS,
with and without dipyridamole, to evaluate microglial
activation. Two days after treatment, cells were fixed
and labeled for the monocytoid marker CD14 and for
nuclei using Hoechst dye. Figure 3 emphasizes the high
purity of the microglia cultures in that virtually all cells
marked by the Hoechst dye were CD14-immunoreactive.
Control microglia were small (Figure 3A), but those acti-
vated with LPS were morphologically larger (Figure 3B).
This LPS-induced change appeared qualitatively to be
prevented by dipyridamole (Figure 3C and 3D).
We quantitated the cellular characteristics using
ImageXpressMICRO (IXM, Molecular Devices, Sunnyvale,
CA), a high-throughput cellular imaging system. Images
from 96-well plates were acquired on the IXM, which
consists of imaging hardware controlled by MetaXpress,
the image analysis software. Images were also quanti-
tated by MATLAB software. The addition of LPS in-
creased cell counts compared with controls (Figure 3E)
(P = 0.0008), a result we have consistently seen in other
experiments. The administration of dipyridamole at
increasing concentrations did not influence the basal or
LPS-induced increase in cell numbers, which further
substantiates that dipyridamole does not affect micro-
glial viability. However, the average microglial cell area
that was increased by LPS (P = 0.0007) was normalized
by increasing concentrations of dipyridamole (Figure 3E).
Although unaltered by dipyridamole in the unactivated
state (P > 0.05), the average intensity of CD14 was
reduced in activated microglia cultures by dipyridamole
(Figure 3F).
In summary, dipyridamole does not alter the cell num-
ber in LPS-treated microglia cultures, but it maintains
morphological alteration, cell area and CD14 intensity
caused by LPS activation at near-normal levels. Because
the effects of dipyridamole are observed only in LPS-
treated and not basal cultures, the results suggest that
dipyridamole is an inhibitor of microglia only when
microglia become activated.
Dipyridamole treatment reduces clinical and histological
scores in EAE correspondent with decreased
microglia activity
In mice treated daily with 100 mg/kg dipyridamole orally
from day 7 postimmunization, the initial onset and peak
of clinical signs were not altered, but continued treatment
reduced clinical severity in the chronic phase of disease
(Figure 4A). There were more and larger foci of inflam-
mation and demyelination in the spinal cords of the
vehicle-treated group compared to the dipyridamole-
treated group (Figure 4B). Histological scores encompassing
the extent of both inflammation and demyelination [27]
were determined across multiple spinal cord specimens
per mouse by a blinded evaluator. The histological score
in vehicle-treated EAE mice was reduced by dipyridamole
treatment (Figure 4C). Across both the dipyridamole- and
vehicle-treated mice, there was a moderate correlation
Figure 3 Transformation of activated microglia to an amoeboid form was reduced when microglia under basal culture conditions or
stimulated with 100 ng/ml LPS were exposed to dipyridamole for 2 days. (A) through (D) CD14 staining. (A) Basal control microglia. (B) LPS
alone. (C) LPS + 5 μM dipyridamole. (D) LPS + 20 μM dipyridamole. Original magnification, ×200. (E) Cell counts of microglia in LPS-stimulated or
basal conditions were unaltered by dipyridamole. In contrast, the increase of cell area (F) and CD14 intensity (G) due to LPS activation was
blocked by dipyridamole. This effect was dose-dependent. Dipyridamole did not alter these features in unstimulated basal microglia cultures.
***P < 0.001 compared to the respective controls. Values are means ± SEM of quadruplicate cultures. NS = not significant.
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between the extent of histology and clinical score
(Figure 4D).
Nine sections per spinal cord were evaluated for
macrophage/microglia reactivity following Iba1 staining.
There was extensive Iba1 staining in sections from
vehicle-treated EAE mice (Figure 5A). This was corrobo-
rated by the larger and amoeboid size of Iba1-stained
cells. Spinal cord sections from dipyridamole-treated
mice had predominantly ramified-shaped, Iba1-stained
cells, indicative of unactivated microglia (Figure 5B).
To quantitate macrophage/microglia reactivity, digital
images of the Iba1-stained sections were analyzed using
the morphological image analysis functions in MATLAB
(Figure 5C and 5D). These were compared with the clin-
ical score. The percentage area of sections stained for
Iba (Figure 5E), as well as the average microglial cell area
(Figure 5F), was reduced in the dipyridamole-treated sec-
tions compared to vehicle-treated sections. The clinical score
correlated with the microglia characteristics (Figure 5E and
5F), supporting a therapeutic effect of dipyridamole in EAE
partly by a reduction of microglia reactivity.
Impact of dose and time of administration on the
therapeutic effect of dipyridamole
When dipyridamole was initiated after peak disease, dipyr-
idamole-treated mice had greater resolution of clinical dis-
ease than vehicle-treated controls (Figure 6). When either
200 mg/kg or 300 mg/kg of oral dipyridamole was admin-
istered prior to onset of clinical symptoms (day 7 after
myelin oligodendrocyte glycoprotein (MOG) immuni-
Figure 4 Dipyridamole reduces clinical and histological scores of EAE. (A) Clinical scores were reduced by 100 mg/kg dipyridamole
(*P < 0.05) (n = 8 per group, mean ± SEM). (B) Hematoxylin and eosin and Luxol fast blue histological staining show multiple cellular infiltrates
and demyelination in the vehicle-treated EAE group (top three panels at ×100, ×200 and ×400 original magnification, respectively, from left to
right), which were reduced by dipyridamole (bottom three panels at ×100, ×200 and ×400 original magnification, respectively, from left to right).
Arrows indicate the infiltrates that are highlighted in the higher-magnification photomicrographs. (C) Histological scores in dipyridamole-treated
animals are reduced compared with vehicle-treated controls. (D) Clinical scores (represented as the sum of daily scores for each mouse over the
entire experiment) correlated with histological scores (P < 0.001).
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zation), the increased dosage significantly reduced the se-
verity of peak EAE disease (Figure 6B). The subsequent
course was also reduced compared to vehicle treatment.
There was no significant difference between the scores of
the mice treated with 200 vs 300 mg/kg dipyridamole
(data not shown).
Figure 5 Macrophage/microglia reactivity in EAE is reduced by dipyridamole. Iba1 staining of thoracic cord shows extensive representation
of macrophage/microglia in the vehicle group (A) upon killing of the mice (at termination of the experiment in Figure 4) compared to that with
dipyridamole treatment (B) (×100 original magnification). The insets in (A) and (B) are high-magnification photomicrographs (×400 original
magnification) that display the amoeboid versus ramified morphology, respectively, of cells. (C) and (D) Thresholded Iba1 staining of (A) and (B),
respectively, to allow the quantitation displayed in (E) and (F). The percentage of spinal cord section occupied by Iba1 staining (E) and the
average macrophage/microglia area (F) are reduced by dipyridamole compared to the EAE-vehicle group. These features correlate with the
clinical scores (sum of daily scores of individual mice).
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Discussion
Microglia populate the brain during early fetal develop-
ment [28] and are quite plastic [29,30]. Unactivated
microglia in postpartum life are ramified in morphology,
but they transition to an amoeboid form in response
to a variety of insults to the nervous system [31].
Unactivated microglia have many processes projecting
from the cell, but, when activated, these processes
retract and thicken and the microglia take on a more
amoeboid, macrophage-like appearance. During CNS
injury, monocytes infiltrate the CNS parenchyma and
become amoeboid macrophages [29-32]. Thus, it becomes
difficult to differentiate the activated microglia from infil-
trated macrophages, and they are referred to collectively
as macrophages/microglia. Recent studies indicate that the
ramified microglia are not quiescent, but continually sur-
vey their microenvironment with extremely motile pro-
cesses and protrusions [33].
In their activated, amoeboid form, microglia have the
capacity to upregulate and release a myriad of secretory
products that can contribute to defense but may also
damage or kill neurons [29-31,34,35]. These products
promote neuroinflammation, and it has been postulated
that inflammatory mediators (cytokines, chemokines and
free radicals) released from activated microglia contrib-
ute to the damage of neural cells. Nonetheless, in some
contexts, microglia have neuroprotective properties
[36,37], and the balance between neurotoxicity and
neuroprotection may be a delicate one.
Blocking the activation of microglia reduces the de-
trimental effects of autoimmune-specific neuroinflam-
mation. EAE is reduced in the CD40-depleted CNS [38]
and in mice where activated microglia/macrophages are
deleted through genetic manipulation [11]. Given these
observations and that activated macrophage/microglia
are present in high and persistent amounts in the CNS
of patients with MS [1,2], a medication that suppresses
microglia or normalizes its activity in MS could be a
useful therapy. However, there is a dearth of such treat-
ments available. One candidate therapy, minocycline,
has microglia-inactivating and other immunomodulatory
properties [13] and is currently in a phase III trial in
early MS.
We now describe that dipyridamole is a candidate
medication to inhibit microglial activation in MS. We
have demonstrated that the activation of microglia in
culture is normalized by dipyridamole treatment. In
mice, dipyridamole inhibits EAE clinically and histologi-
cally, and this effect is correlated with reduced signs of
macrophage/microglia activation examined by Iba1 im-
munohistochemistry. Other features of dipyridamole
further support its potential utility in MS, and, because
it is already in long-term use for stroke prevention, its
potential chronic use in patients with MS has a clinical
precedent. Dipyridamole also has antioxidant effects
[39], and it inhibits the expression of matrix metal-
loproteinase 9 (MMP-9) [40,41]. These molecules are
thought to contribute to MS pathogenesis. Dipyrid-
amole has also been shown to suppress the release of
soluble CD40 ligand [42], an effect that can reduce
antigen presentation and inflammatory cascades.
Summary of the effects of dipyridamole on microglia
and experimental autoimmune encephalomyelitis
Reduces the morphological changes of microglia upon
their activation.
Attenuates a spectrum of cytokines and chemokines
secreted by activated microglia.
Prevents the activation of microglia, but not their
transition from one subtype to another.
Figure 6 Impact of dipyridamole dose and the time of
treatment initiation on EAE. (A) The clinical scores favored the
dipyridamole-treated animals (n = 5 per group, mean ± SEM) after 8
d of treatment when initiation of treatment (100 mg/kg) was
delayed until day 20 of EAE. (B) The clinical score in animals treated
on day 7 of EAE induction with either 200 mg/kg (not shown) or
300 mg/kg dipyridamole is reduced at both the peak of disease and
postpeak (n = 8 per group, mean ± SEM). *P < 0.05, **P < 0.01.
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Decreases the severity of EAE when given prior to the
onset of clinical signs.
Reduces the severity of chronic EAE when initiated
after clinical signs are apparent.
Prevents the activation of microglia that occurs in EAE.
In recent years, macrophages have been subdivided
into M1 and M2 phenotypes [43-45]. M1 is considered
proinflammatory, produces proinflammatory cytokines
such as TNF-α and is a strong expressor of C-C chemo-
kine receptor type 2 (CCR2). M2 is thought to be regula-
tory/anti-inflammatory, to secrete regulatory cytokines
such as IL-10, and express prominently C-X3-C motif
chemokine receptor 1 (CX3CR1). Our data suggest that
dipyridamole reduces activated microglia to a normal
state, rather than being a regulator of the differentiation
of cells into those that are M1 or M2. For example, both
TNF-α and IL-10 are decreased in activated microglia by
dipyridamole (Figure 2).
It is not known how much dipyridamole enters into
the CNS after oral administration in humans or mice.
However, given its highly lipophilic nature, a feature
that favors entry into the CNS, it is anticipated that di-
pyridamole crosses the blood-brain barrier to affect
microglia within. That said, we cannot exclude the pos-
sibility that some of the benefits of dipyridamole in
EAE could be accounted for by peripheral mechanisms,
such as the reduction of peripheral blood monocyte ac-
tivity and hence their migration into the CNS to be-
come macrophages. That dipyridamole did not affect
the initial rise of clinical signs in a dose that attenuated
final clinical and histological outcomes, however, sug-
gests that the peripheral mechanisms that give rise to
the onset of clinical signs do not need to be affected by
dipyridamole. Furthermore, because treatment with di-
pyridamole was initiated on day 7, suppression of the
initiating peripheral immunological mechanisms could
not be explained by treatment with dipyridamole.
Platelets have been proposed to have roles in MS [46].
In this regard, platelets produce a variety of MMP mem-
bers that are implicated in MS, and platelets also express
several chemokine receptors that can respond to che-
mokines known to be elevated in MS [46]. There
appears to be chronic platelet activation in MS, as
evidenced by elevation of platelet microparticles and the
platelet activation marker CD62L [47]. Recently, Langer
et al. [48] found platelets in MS and EAE brain lesions
and demonstrated that the depletion of platelets in mice
ameliorated EAE disease course. Thus, the extent to
which the antiplatelet activity [17] of dipyridamole helps
account for its effectiveness in EAE remains to be deter-
mined. The results of our present study extend the
spectrum of activity of dipyridamole to include microglia
inhibition.
Conclusions
In summary, we have found that dipyridamole normal-
izes macrophage/microglia activity and reduces the se-
verity of EAE. Dipyridamole may counter the persistent
activation of macrophage/microglia in MS, a feature that
is not adequately treated by current medications proven
to be effective in MS. One should be cautious when ex-
trapolating from the current animal studies to humans,
however, and dipyridamole may not work in MS. Given
that microglial activation is a feature of many neuro-
logical conditions [48], dipyridamole should be tested
across a spectrum of disorders where it is pertinent to
normalize the activity of activated microglia.
Methods
Preparation and treatment of human microglia
Microglia of over 95% purity were isolated from the
brains of adult humans undergoing resection to treat
intractable epilepsy or from the brains of human fetuses
of 10 to 18 wk gestational age, as previously described
[49,50]. The use of these specimens was approved by the
University of Calgary Research Ethics Board. Cells were
plated in 96-well flat-bottomed black plates (BD
Pharmingen, San Jose, CA, USA) at a density of 10,000
per well. The feeding medium used was minimum essen-
tial medium (MEM) supplemented with 10% fetal bovine
serum, 1% penicillin/streptomycin, 0.1% dextrose, 1×
nonessential amino acids, 10 μM glutamine and 1 mM
sodium pyruvate (called complete MEM).
Where indicated, adherent cells were treated with
100 ng/ml of the Toll-like receptor 4 agonist LPS
(100 ng/ml); the Toll-like receptor 2 agonist Pam; a synthetic
tripalmitoylated cysteine-, serine- and lysine-containing
peptide; and with varying concentrations of dipyridamole.
All treatments with dipyridamole were done 30 min prior
to the addition of LPS or Pam. The pretreatment period
was necessary because LPS and Pam are potent activa-
tors that trigger signaling cascades minutes after en-
gagement of Toll-like receptors on cells. All chemicals
used were obtained from Sigma-Aldrich (St Louis, MO,
USA). Cell-conditioned media were collected after 24 h
and used for cytokine analyses. The remaining cells
were fixed and then stored in phosphate-buffered saline
(PBS) until staining was conducted (within 24 h of
fixation).
Phagocytosis Assay
Human adult microglia were plated at a density of
10,000 per well in 200 μl of the medium described above
in flat-bottomed 96-well plates and left untreated for
48 h. The cells were then incubated for 48 h with LPS
(100 ng/ml) or with the combination of LPS (100 ng/ml)
and 10 μM dipyridamole (added 30 min before LPS).
Ten microliters of yellow-green phagocytotic fluorospheres
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(Invitrogen, Carlsbad, CA, USA) were then added. After
2 h of incubation with the fluorospheres, the wells were
washed twice with PBS, fixed in 4% paraformaldehyde for
10 min and then washed again with PBS. Rabbit anti-Iba1
(1 h at 1:100; Wako Chemicals USA, Richmond, VA,
USA) and donkey anti-rabbit Texas Red (1 h at 1:200)
were used to label the microglia. The Iba1 antibody labels
ionized calcium-binding adapter molecule 1 that is se-
lective to macrophage/microglia. Hoechst dye (10 min
at 1:100) was used to label the nuclei. Images were
acquired using the ImageXpress Micro XL Widefield
High Content Screening System (Molecular Devices).
Immunofluorescence cell labeling and quantification
of image parameters
Fixed cells were stained for CD14 (1:40; BD Pharmingen),
a cell surface LPS-binding coreceptor on monocytoid cells
and secondary antibody before cell nuclei were labeled
using Hoechst dye (1:100 for 10 min). The plate wells were
then scanned automatically using the ImageXpressMICRO
controlled by MetaXpress hardware. Images were stored
separately in TIFF file format as single-image planes for
each wavelength. Image background was removed by
using an image-flattening algorithm to permit between-
well quantitative comparison. All image analysis was
conducted using MATLAB and confirmed with test im-
ages, manual measurements and counting, and other
software when available. Cell counts were based on
colocalization of Hoechst dye with CD14. Cell areas and
average cell intensities were measured by manually
preselecting a threshold above local background for each
96-well plate, confirming appropriate thresholds by visual
inspection of images and calculating average areas using
standard MATLAB segmentation algorithms, morpho-
logical operators and measurement routines. Similar ana-
lyses were performed on images of spinal tissue stained
for Iba1.
ATP luminescence assay
Cell viability was assessed by use of an ATP assay kit ac-
cording to the instructions of the manufacturer (CellTiter-
Glo Luminescent Cell Viability Assay; Promega, Madison,
WI, USA).
Cytokine analyses
Cytokine concentrations within the microglia condi-
tioned medium were measured with a single-cytokine
ELISA and a multiplex ELISA. The TNF-α ELISA was
done using a KHC3011 kit from Invitrogen. Condi-
tioned media were also subjected to a multiplex human
cytokine panel (LHC0009), permitting simultaneous
measurement of 25 different cytokines and chemokines
(Invitrogen).
Disease induction and EAE analyses
EAE was induced in female C57BL/6 mice (The Jackson
Laboratory, Bar Harbor, ME, USA), ages 8 to 9 wk, by
subcutaneous (s.c.) injection of 50 μg MOG35–55 in
Freund’s Complete Adjuvant medium (Thermo Fisher
Scientific, Rockford, IL, USA) on day 0. Intraperitoneal
(i.p.) pertussis toxin (0.1 μg/200 μl; List Biological La-
boratories, Hornby, ON, Canada) was administered on
days 0 and 2. To increase the sensitivity of measure-
ment, animals were assessed daily using a 15-point dis-
ease score scale [27,51] instead of the more commonly
used 5-point scale. The 15-point scale differentiates indi-
vidual limb disability rather than grouping both fore- or
hindlimbs together. The 15-point scale (0 to 15) is the
sum of the disease state for the tail (scored from 0 to 2)
and each limb (scored from 0 to 3), and death is scored
at 15. All animals were handled in accordance with the
policies outlined by the Canadian Council for Animal
Care and the University of Calgary.
Dipyridamole was suspended in 0.5% carboxymethyl-
cellulose and, unless otherwise stated, was given to mice
through oral gavage daily beginning on day 7 in 100 μl
of suspension at a final dose of 100, 200 or 300 mg/kg.
These doses were chosen because the uppermost safety
limit for dipyridamole in mice is 400 mg/kg (lethal dose
50, or LD50, is 700 mg/kg) [52].
Histology of tissue from control and EAE mice
Animals were killed by giving them an overdose of keta-
mine/xylazine (200 and 10 mg/kg, respectively). Spinal
cords were removed and dissected into preselected parts
to maximize opportunities for histological analyses, and
the thoracic blocks (1.0 cm) were immersion-fixed in
10% buffered formalin and then embedded in paraffin.
Thoracic sections were cut on a microtome at 6-μm
thickness and mounted on glass slides. For each mouse,
the thoracic cord was cut longitudinally through the en-
tire dorsal–ventral axes. Six sequential series of sections,
spaced 50 μm apart, were generated. One series was
processed for histological staining with hematoxylin-
eosin and Luxol fast blue as previously described [27,51],
and another was processed for Iba1. We focused our at-
tention on the T3/T4 segments.
Images of the sections were captured using an Olym-
pus BH2 microscope (Olympus America, Center Valley,
PA, USA) and QCapture Pro version 5.1.1.14 software
(QImaging, Surrey, BC, Canada). For semiquantitative
assessment of the extent of inflammation and demyelin-
ation in the spinal cord, all stained longitudinal sections
from the same coded mouse were evaluated using a
scoring system described previously [27]. In this regard,
the location (pia vs parenchyma) and number of inflam-
matory aggregates per section were documented, with par-
enchymal inflammation and larger and higher number of
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aggregates being assigned greater inflammation scores.
The reader is referred elsewhere for the details [27]. Six
sections per spine were evaluated by a blinded observer,
and the average score per mouse was documented.
Statistical analysis
Statistical analysis was performed using R version 2.8.1
software (The R Foundation for Statistical Computing,
Vienna, Austria) and MATLAB version 7.7 software.
Statistical differences for cells in culture (Figures 1, 2 and
3) were addressed using ANOVA with the Bonferroni
correction for multiple comparisons. Statistical differences
between groups of mice in the EAE experiments (Figures 4,
5 and 6) were evaluated using a nonparametric Mann-
Whitney U test. An α score of 0.05 was selected for statis-
tical significance.
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